Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-2113
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AD-2113** is an Addpharma investigational oral pain-treatment product being evaluated as an active comparator in a randomized, double-blind Phase 2 dose-selection trial for knee osteoarthritis. The supplied trial context identifies the AD-211 program as a **celecoxib + eperisone** combination. Celecoxib is a selective cyclooxygenase-2 inhibitor that reduces prostaglandin-mediated pain and inflammation, while eperisone is a centrally acting skeletal-muscle relaxant used to reduce muscle hypertonicity. The precise ingredient strengths and formulation details for the AD-2113 presentation have not been publicly specified.
- Other names
- Celecoxib/Eperisone/Rebamipide combination
02
Targets
CaV (Voltage-gated calcium channel protein complex)PGHS-1 (Prostaglandin G/H Synthase 1)NF-κBNaV (Voltage-gated sodium channels)CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on AD-2113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-2113.